Psychedelic therapy is legally available in seven distinct jurisdictions in 2026, and the access pathway differs in each. Oregon and Colorado run state-licensed psilocybin services centers. New Mexico activated its medical program in 2025. Australia became the first country to allow MDMA and psilocybin prescribing in 2023. Switzerland permits compassionate use. Ketamine therapy remains legal in all 50 United States as a Schedule III off-label prescription (DEA, 2024). The Trump administration's April 2026 executive order accelerated the FDA psychedelic pathway, but MDMA approval has not yet landed.
The question founders keep asking me is simple: where can I do this without breaking the law? The answer is more specific than the news cycle suggests. Decriminalization headlines from Denver, Seattle, Oakland, and Washington DC do not mean therapy is available. They mean criminal penalties have been reduced for personal possession. That is not the same as a clinic you can walk into and pay for treatment. This guide separates those categories carefully.
If you've read about psychedelics for entrepreneurs and want to know where to actually go, this is the operational map. Pricing varies between $1,500 in Oregon group sessions and $25,000 for full Australian MDMA protocols. Wait times range from two weeks to nine months. Travel requirements differ. Documentation requirements differ. Privacy implications differ. The picture is workable, just not as simple as a single approval announcement.
- Seven jurisdictions allow legal psychedelic therapy in 2026: Oregon, Colorado, New Mexico (psilocybin), Australia (MDMA + psilocybin prescribing), Switzerland, Canada (compassionate use), and ketamine in all 50 US states.
- Oregon services centers opened in January 2023 under Measure 109. The Oregon Health Authority licensed 31 service centers by end of 2024 (Oregon Health Authority, 2024).
- Australia legalized MDMA and psilocybin prescribing through the TGA Authorised Prescriber scheme on July 1, 2023, becoming the first country to do so (TGA, 2023).
- MDMA-assisted therapy is not yet broadly approved in the US following the August 2024 FDA Complete Response Letter to Lykos. The April 2026 Trump executive order accelerated the pathway.
- Decriminalization is not legalization. Both Oakland and Denver decriminalized possession, but neither created legal therapy services. The difference matters for founders.
Why Does Legal Versus Decriminalized Actually Matter?
The Drug Policy Alliance documented at least 25 US cities and counties that decriminalized psychedelics between 2019 and 2024, but only three states established legal therapy access in that same window (Drug Policy Alliance, 2024). Decriminalization removes criminal penalties for personal possession. Legalization for therapy creates a regulated pathway to receive treatment from a licensed provider. These are different legal categories with different practical consequences for someone seeking actual help.
In a decriminalized jurisdiction, you cannot be arrested for personal possession of small quantities. You also cannot legally purchase the substance, receive it from a licensed clinician, or access it through any regulated service. Underground access continues, with all of its quality, safety, and integration limitations. Decriminalization is a harm-reduction measure, not a healthcare framework. The distinction surfaces immediately when someone tries to find a provider in a decriminalized-only jurisdiction.
Legal therapy access, by contrast, means a documented chain of custody, licensed facilitators, regulatory oversight, and a legal record of treatment. This matters more than most clients initially expect. If you ever need to disclose a medical history, want insurance involvement, or work in a regulated profession that involves disclosure requirements, the difference between underground and legal access becomes important in concrete ways.
The Drug Policy Alliance reports that at least 25 US cities and counties decriminalized psychedelic substances between 2019 and 2024, but only Oregon, Colorado, and New Mexico established legally accessible therapy programs during the same period (Drug Policy Alliance, 2024). Decriminalization measures reduce criminal penalties for personal possession but do not create a licensed pathway to receive treatment from a qualified provider. The two categories are routinely conflated in coverage, leading to confusion about where therapy is actually available.
Where Is Psychedelic Therapy Legal in the US in 2026?
Three US states have legal psilocybin therapy programs operating in 2026: Oregon, Colorado, and New Mexico. The Oregon Health Authority reported 31 licensed psilocybin service centers and over 290 licensed facilitators by the end of 2024 (Oregon Health Authority, 2024). Colorado activated its first healing centers in mid-2024 under Proposition 122. New Mexico's medical psilocybin program, established by SB 27, began accepting patients in 2025. Ketamine remains separately legal nationwide as an off-label prescription.
Oregon Measure 109: The First Operational US Program
Oregon voters passed Measure 109 in November 2020, creating the first legal psilocybin services framework in the United States. The Oregon Health Authority Psilocybin Services section began licensing service centers and facilitators in January 2023. Sessions take place at licensed centers, with a trained facilitator present, after a preparation meeting and before an integration meeting. The program does not require a medical diagnosis, which makes it different from a strictly therapeutic model.
Cost per session in Oregon ranges from $1,500 to $3,500, depending on group versus individual format and the specific service center. Wait times for first sessions at established centers run between three and ten weeks as of early 2026. Oregon residency is not required. International and out-of-state clients can legally access sessions by traveling to Oregon for the dosing day and surrounding meetings.
Colorado Proposition 122: The Natural Medicine Program
Colorado voters approved Proposition 122 in 2022, creating the state's Natural Medicine Program. The Colorado Department of Revenue Natural Medicine Division began licensing healing centers in 2024. The program is broader than Oregon's in stated scope, with future provisions for additional natural medicines like DMT, mescaline, and ibogaine. As of 2026, only psilocybin services are operational.
Colorado pricing is comparable to Oregon, with session costs typically between $1,800 and $3,800. Healing center density is lower than Oregon's, but the program permits both center-based and certain home-based facilitated experiences, which Oregon does not. Wait times in Colorado tend to be longer than Oregon as of May 2026 because the licensed facilitator pool is still growing relative to demand.
New Mexico SB 27: The Newest US Pathway
New Mexico passed SB 27 in 2024, establishing the Medical Psilocybin Treatment Act. The New Mexico Department of Health began accepting patient applications in 2025. The program is narrower than Oregon and Colorado in target population: it specifically serves patients with PTSD, treatment-resistant depression, end-of-life distress, and substance use disorders. This makes it functionally a medical model rather than a service center model.
The MDMA Question: Post-CRL Status
MDMA-assisted therapy remains not broadly legal in the United States as of May 2026. The FDA issued a Complete Response Letter to Lykos Therapeutics in August 2024, requesting additional Phase 3 data before approving MDMA for PTSD. The Trump administration's April 2026 executive order directed the FDA to accelerate the psychedelic medicine pathway, including establishing new review timelines for breakthrough-therapy-designated substances. A revised MDMA approval timeline is under active review, but no approval is in effect as of this article's publication. Expanded Access programs at specific clinical sites remain the only legal pathway to MDMA therapy in the United States during 2026.
How Did Australia Become the First Country to Legalize MDMA Prescribing?
Australia's Therapeutic Goods Administration rescheduled MDMA and psilocybin to Schedule 8 for prescribed therapy on July 1, 2023, making Australia the first country in the world to allow legal prescribing of MDMA for PTSD and psilocybin for treatment-resistant depression (TGA, 2023). Prescribing happens under the Authorised Prescriber scheme, which requires individual psychiatrist authorization, human research ethics committee approval, and TGA confirmation. The pathway is real but narrow.
Cost for a full MDMA-assisted therapy protocol in Australia ranges from approximately AUD 15,000 to AUD 35,000 in 2026 pricing. This includes three dosing sessions, preparation, and integration. Most providers also charge separately for psychiatric assessment and treatment plan documentation. Out-of-pocket payment is the rule. Australian private health insurance does not cover psychedelic-assisted therapy in most cases, although a few insurers have begun limited reimbursement for psychiatric components.
For Americans considering Australia, the practical considerations are visa, travel time, and clinic capacity. The Authorised Prescriber list is publicly maintained but small relative to demand. Wait times for first consultation can run three to six months at established practices. International clients typically need to coordinate at least two trips: an initial consultation and assessment trip, followed by a treatment trip of two to three weeks for full protocol completion.
Legal status changes. The information in this article reflects regulatory status as of May 13, 2026 based on the named government sources. Before booking any session or traveling for treatment, verify current legal status with a qualified attorney in your home jurisdiction and the treatment jurisdiction. This article is not legal advice.
Switzerland and Canada: How Do Compassionate Use Pathways Work?
Switzerland's Federal Office of Public Health (BAG) has authorized compassionate use of MDMA and psilocybin under Section 8(5) of the Narcotics Act since 2014, with the program expanded substantially in recent years (Swiss Federal Office of Public Health, 2023). Authorized Swiss psychiatrists can apply for individual patient permits to use MDMA, psilocybin, or LSD in psychotherapeutic treatment. Canada operates a parallel pathway through Section 56 of the Controlled Drugs and Substances Act, with limited exemptions granted for end-of-life distress, treatment-resistant depression, and specific research contexts.
Switzerland's compassionate use program is more accessible in practice than Canada's. Several Swiss psychiatric practices in Zurich, Bern, and Basel have established workflows for international patients. Cost for a full MDMA or psilocybin protocol in Switzerland typically ranges from CHF 20,000 to CHF 40,000. The program is narrow by design: it requires documented treatment resistance and psychiatric assessment, not general interest. This rules it out for founders seeking purely exploratory or performance-related sessions.
Canada's Section 56 pathway is genuinely limited as of 2026. Health Canada has granted exemptions to a relatively small number of patients, primarily for end-of-life psychological distress and treatment-resistant depression. The TheraPsil organization has documented the application process, but approval rates remain low and the timeline runs four to nine months from application to authorization. For most clients, Canada is not a practical legal pathway in 2026.
How Do Legal Psychedelic Therapy Jurisdictions Compare?
The five most accessible legal jurisdictions in 2026 differ significantly in cost, wait time, substance availability, and documentation requirements. A complete comparison reveals that no single jurisdiction is optimal for every situation: Oregon offers the lowest cost and shortest wait times for psilocybin, Australia provides the only legal MDMA pathway broadly accessible to international clients, Switzerland combines high clinical standards with compassionate-use flexibility, and ketamine offers all-50-states access at the lowest travel cost. The matrix below summarizes the operational differences.
| Jurisdiction | Substance | Cost Range | Wait Time | Travel | Documentation |
|---|---|---|---|---|---|
| Oregon, USA | Psilocybin | $1,500 - $3,500 per session | 3 - 10 weeks | Domestic (US clients) | Service center records only; no diagnosis required |
| Colorado, USA | Psilocybin | $1,800 - $3,800 per session | 6 - 14 weeks | Domestic (US clients) | Healing center records; no diagnosis required |
| New Mexico, USA | Psilocybin (medical) | Pricing developing in 2026 | 2 - 6 months | Domestic (US clients) | Medical diagnosis required; clinical record created |
| Australia | MDMA + Psilocybin | AUD 15,000 - 35,000 full protocol | 3 - 6 months | International; 2 trips typical | Psychiatric diagnosis + Authorised Prescriber records |
| Switzerland | MDMA, Psilocybin, LSD | CHF 20,000 - 40,000 full protocol | 3 - 6 months | International; Schengen visa | Treatment-resistance documentation required |
| Ketamine (all US) | Ketamine | $400 - $800 per infusion | 1 - 4 weeks | Local (all 50 states) | Off-label prescription; clinical record created |
The matrix reveals what most coverage misses. If cost is the dominant constraint and psilocybin is appropriate for the use case, Oregon is the operationally simplest choice. If MDMA is specifically required, either Australia or Switzerland, with Australia generally easier for English-speaking clients. If travel is the dominant constraint, ketamine in your home state is the only realistic option. If documentation privacy matters, Oregon and Colorado create the least invasive clinical records because they do not require diagnosis-based access.
The Oregon Health Authority Psilocybin Services Section reported 31 licensed service centers and over 290 licensed facilitators operating across the state by the end of 2024 (Oregon Health Authority, 2024). The program does not require medical diagnosis, distinguishing it from the medical models in New Mexico and the prescribing schemes in Australia and Switzerland. This makes Oregon the operationally simplest pathway in 2026 for clients without treatment-resistant conditions, although the wait times and pricing remain non-trivial considerations.
Why Is Ketamine the Most Accessible Legal Option in 2026?
Ketamine is a DEA Schedule III substance, the lowest restriction tier of any psychedelic with established therapeutic application, and any licensed US physician can prescribe it off-label (DEA, 2024). Spravato (esketamine, the nasal spray formulation) holds FDA approval for treatment-resistant depression and depression with suicidality. Ketamine clinics operate in all 50 states. This combination makes ketamine the most accessible legal psychedelic therapy in the United States in 2026, regardless of state-level psilocybin or MDMA legislation.
Cost per IV ketamine infusion typically runs $400 to $800 in 2026, with most clinical protocols requiring six to eight sessions for depression and PTSD indications. Spravato is covered by some insurance plans when prescribed for its FDA-approved indications, while off-label ketamine is generally paid out of pocket. Travel is local. Wait times at established clinics run one to four weeks. Documentation is clinical, since a prescription record is created.
"Ketamine is the option founders most often dismiss and most often need. It's local, it's legal in every state, it doesn't require diagnostic gymnastics, and the integration question is identical to any other psychedelic protocol."
The integration considerations for ketamine are functionally similar to psilocybin and MDMA, although the experience itself is shorter and the somatic component slightly different. Ketamine integration work follows the same neuroplasticity-window logic that applies to longer-acting substances. The fact that ketamine is medically familiar makes some clients underweight it. The mechanism is genuinely psychedelic at therapeutic doses, and the implicit memory updating that the substance enables is real.
How Should Founders Choose a Legal Jurisdiction?
Choosing a jurisdiction comes down to four operational questions in priority order: which substance does the use case actually require, what level of clinical documentation are you comfortable creating, how much travel can the calendar absorb, and what is the realistic budget. In 900+ integration sessions across two years of practice, the founders who chose well shared one common trait: they answered the substance question first, not the cost question. The substance question constrains the jurisdiction list. Cost, wait time, and travel are then optimized within that constrained list, not before it.
If the use case is trauma-adjacent or PTSD-coded, MDMA is the substance with the deepest clinical evidence base. That points to Australia or Switzerland as the only legal pathways in 2026, with expanded-access trials as the alternative in the US. If the use case is depression-coded or general exploratory, psilocybin is the better-evidenced substance, which points to Oregon, Colorado, or New Mexico domestically, or Switzerland internationally. If trauma overlap is significant and travel is impossible, ketamine is the only realistic legal option in the United States.
The documentation question matters more than most founders initially weigh it. Australia, Switzerland, New Mexico, and ketamine clinics all create medical records that include a diagnosis or treatment indication. Oregon and Colorado service centers do not. For founders in regulated professions, security clearance contexts, or pre-IPO companies with specific disclosure expectations, this is not a minor distinction. The right answer is not the same for everyone, but the question deserves serious attention before booking.
Wait time and cost are the easier optimizations once the substance and documentation constraints are set. Oregon offers the shortest wait times for psilocybin in 2026. Ketamine clinics offer the shortest wait times for any psychedelic therapy in the United States. Group sessions reduce psilocybin costs in Oregon and Colorado by 30 to 50 percent versus individual sessions. International protocols cost more but include treatment density that home-state options sometimes lack. Total budget for a meaningful protocol with integration support typically lands between $3,500 (ketamine) and $40,000 (Switzerland MDMA), with most domestic psilocybin pathways in the $5,000 to $8,000 range.
Whatever jurisdiction you choose, the integration work is the part that determines whether the legal session produces lasting behavioral change. Finding the right integration therapist is at least as important as choosing the legal pathway. Legal access creates the conditions for change. Integration is what makes the change land. The two questions are inseparable in practice, although they're routinely treated separately in coverage and in clinic offerings.
Australia's Therapeutic Goods Administration rescheduled MDMA and psilocybin to Schedule 8 for prescribed therapy on July 1, 2023, making Australia the first country in the world to formally authorize psychiatrist prescribing of MDMA for PTSD and psilocybin for treatment-resistant depression (TGA, 2023). The Authorised Prescriber scheme requires individual psychiatrist authorization, ethics committee approval, and TGA confirmation. This pathway is narrow but real, and remains operational for international clients in 2026.